DiaMedica Therapeutics (DMAC) Stock Forecast, Price Target & Predictions
DMAC Stock Forecast
DiaMedica Therapeutics stock forecast is as follows: an average price target of $8.33 (represents a 96.00% upside from DMAC’s last price of $4.25) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
DMAC Price Target
The average price target for DiaMedica Therapeutics (DMAC) is $8.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $7.00. This represents a potential 96.00% upside from DMAC's last price of $4.25.
DMAC Analyst Ratings
According to 4 Wall Street analysts, DiaMedica Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DMAC stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DiaMedica Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 07, 2024 | Bill Chappell | Truist Financial | $10.00 | $4.42 | 126.46% | 135.29% |
| Oct 07, 2024 | Matthew Caufield | H.C. Wainwright | $7.00 | $4.36 | 60.55% | 64.71% |
| Mar 21, 2024 | Alex Nowak | Craig-Hallum | $8.00 | $2.69 | 197.40% | 88.24% |
The latest DiaMedica Therapeutics stock forecast, released on Oct 07, 2024 by Bill Chappell from Truist Financial, set a price target of $10.00, which represents a 126.46% increase from the stock price at the time of the forecast ($4.42), and a 135.29% increase from DMAC last price ($4.25).
DiaMedica Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $8.50 | $8.50 | $8.33 |
| Last Closing Price | $4.25 | $4.25 | $4.25 |
| Upside/Downside | 100.00% | 100.00% | 96.00% |
In the current month, the average price target of DiaMedica Therapeutics stock is $8.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 100.00% increase as opposed to DiaMedica Therapeutics's last price of $4.25. This month's average price target is down 0.00% compared to last quarter, and up 2.04% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 07, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jun 22, 2023 | Oppenheimer | - | Outperform | Upgrade |
| Jun 22, 2023 | Oppenheimer | - | Hold | Upgrade |
| Jul 07, 2022 | Lake Street | Buy | Buy | Hold |
| Jul 07, 2022 | Craig-Hallum | Buy | Buy | Hold |
DiaMedica Therapeutics's last stock rating was published by H.C. Wainwright on Oct 07, 2024. The company Initialise its DMAC rating from "null" to "Buy".
DiaMedica Therapeutics Financial Forecast
DiaMedica Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
| High Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
| Low Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
DiaMedica Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DMAC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
DiaMedica Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict DMAC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than DiaMedica Therapeutics's previous annual EBITDA (undefined) of $NaN.
DiaMedica Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-5.33M | $-6.85M | $-6.85M | $-6.85M | $-7.23M | $-8.38M | $-7.23M | $-7.61M | $-6.57M | $-5.90M | $-5.96M |
| High Forecast | $-5.33M | $-6.85M | $-6.85M | $-6.85M | $-7.23M | $-8.38M | $-7.23M | $-7.61M | $-6.57M | $-5.11M | $-5.96M |
| Low Forecast | $-5.33M | $-6.85M | $-6.85M | $-6.85M | $-7.23M | $-8.38M | $-7.23M | $-7.61M | $-6.57M | $-6.29M | $-5.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
DiaMedica Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DMAC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
DiaMedica Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
DiaMedica Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DMAC last annual SG&A of $NaN (undefined).
DiaMedica Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.14 | $-0.18 | $-0.18 | $-0.18 | $-0.19 | $-0.22 | $-0.19 | $-0.20 | $-0.17 | $-0.15 | $-0.16 |
| High Forecast | $-0.14 | $-0.18 | $-0.18 | $-0.18 | $-0.19 | $-0.22 | $-0.19 | $-0.20 | $-0.17 | $-0.13 | $-0.16 |
| Low Forecast | $-0.14 | $-0.18 | $-0.18 | $-0.18 | $-0.19 | $-0.22 | $-0.19 | $-0.20 | $-0.17 | $-0.17 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, DiaMedica Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DMAC previous annual EPS of $NaN (undefined).
DiaMedica Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.52 | $3.67 | 605.77% | Buy |
| MIST | Milestone Pharmaceuticals | $1.44 | $10.00 | 594.44% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.65 | $38.80 | 164.85% | Buy |
| TERN | Terns Pharmaceuticals | $6.94 | $14.25 | 105.33% | Buy |
| DMAC | DiaMedica Therapeutics | $4.25 | $8.33 | 96.00% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| IKT | Inhibikase Therapeutics | $2.64 | $5.00 | 89.39% | Buy |
| IOVA | Iovance Biotherapeutics | $11.19 | $21.00 | 87.67% | Buy |
| MCRB | Seres Therapeutics | $0.82 | $1.25 | 52.44% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.67 | $21.67 | 38.29% | Buy |
| HOOK | HOOKIPA Pharma | $3.84 | $3.00 | -21.88% | Buy |
DMAC Forecast FAQ
Is DiaMedica Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, DiaMedica Therapeutics (DMAC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of DMAC's total ratings.
What is DMAC's price target?
DiaMedica Therapeutics (DMAC) average price target is $8.33 with a range of $7 to $10, implying a 96.00% from its last price of $4.25. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DiaMedica Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DMAC stock, the company can go up by 96.00% (from the last price of $4.25 to the average price target of $8.33), up by 135.29% based on the highest stock price target, and up by 64.71% based on the lowest stock price target.
Can DiaMedica Therapeutics stock reach $6?
DMAC's average twelve months analyst stock price target of $8.33 supports the claim that DiaMedica Therapeutics can reach $6 in the near future.
What is DiaMedica Therapeutics's current price target trend?
2 Wall Street analysts forecast a $8.5 price target for DiaMedica Therapeutics (DMAC) this month, up 100.00% from its last price of $4.25. Compared to the last 3 and 12 months, the average price target increased by 100.00% and increased by 96.00%, respectively.
What are DiaMedica Therapeutics's analysts' financial forecasts?
DiaMedica Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.455M (high $-30.455M, low $-30.455M), average SG&A $0 (high $0, low $0), and average EPS is $-0.8 (high $-0.8, low $-0.8). DMAC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $54M (high $54M, low $54M), average EBITDA is $0 (high $0, low $0), average net income is $-25.886M (high $-25.886M, low $-25.886M), average SG&A $0 (high $0, low $0), and average EPS is $-0.68 (high $-0.68, low $-0.68).